Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Virol. Jul 25, 2022; 11(4): 204-207
Published online Jul 25, 2022. doi: 10.5501/wjv.v11.i4.204
Management of SARS-CoV-2 infection is a major challenge in patients with lymphoid malignancies: Warrants a clear therapeutic strategy
Tarun Sahu, Henu Kumar Verma, Bhaskar Lvks
Tarun Sahu, Physiology, All India Institute of Medical Science, Raipur 492001, Chhattisgarh, India
Henu Kumar Verma, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Munich 80331, Bayren, Germany
Bhaskar Lvks, Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur 495001, Chhattisgarh, India
Author contributions: Sahu T, Verma HK, Lvks B wrote and revised the letter.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Henu Kumar Verma, PhD, Research Scientist, Department of Immunopathology, Institute of Lung Health and Immunity, Comprehensive Pneumology Center, Helmholtz Zentrum, Ingolstädter Landstrasse 1, Munich 80331, Bayren, Germany, henu.verma@yahoo.com
Received: June 5, 2021
Peer-review started: June 5, 2021
First decision: July 27, 2021
Revised: July 28, 2021
Accepted: May 27, 2022
Article in press: May 27, 2022
Published online: July 25, 2022
Core Tip

Core Tip: Patients with hematologic conditions are two times more likely than others to be admitted to the hospital. They are being treated with anti-cancer drugs, which weakens their immune system. As a result, these patients are always at risk of coronavirus disease 2019 (COVID-19). As we know, the COVID-19 is very lethal, and hematological malignancies are likely to increase the risk of negative outcomes from this viral infection. Currently, there are no guidelines for treating COVID-19 infected patients with hematological malignancies.